The Controlled Release Drug Delivery by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Controlled Release Drug Delivery Market:
According to The Business Research Company’s Controlled Release Drug Delivery , The controlled release drug delivery market size has grown rapidly in recent years. It will grow from $59.2 billion in 2023 to $66.18 billion in 2024 at a compound annual growth rate (CAGR) of 11.8%. The growth in the historic period can be attributed to pioneering drug delivery systems, early polymer-based formulations, introduction of microencapsulation techniques, emergence of transdermal delivery, regulatory approvals and standardization..
The controlled release drug delivery market size is expected to see rapid growth in the next few years. It will grow to $105.06 billion in 2028 at a compound annual growth rate (CAGR) of 12.2%. The growth in the forecast period can be attributed to shift towards personalized medicine, technological integration for patient convenience, expansion of biologics and biosimilars, market expansion in developing regions, advancements in polymer science.. Major trends in the forecast period include biodegradable and biocompatible materials, nanotechnology advancements, personalized medicine and targeted therapies, advances in implantable devices, innovative encapsulation techniques.
The rising prevalence of chronic diseases is expected to propel the growth of the controlled release drug delivery market. Chronic diseases are also known as noncommunicable diseases. It refers to conditions such as heart disease, cancer, and diabetes diseases lasting more than a year and requiring continuing medical care, limiting everyday activities, or both. Controlled-release drug delivery is crucial for treating chronic diseases. For patients with chronic illnesses that require years of treatment or those who reside in areas with limited resources and access to healthcare, drug delivery formulations that allow prolonged medication release are essential. For instance, in September 2022, according to report shared by the World Health Organization (WHO), a Switzerland-based health-specialized agency, every year, 41 million people die from chronic diseases, which accounts for 74 percent of all fatalities worldwide. Before the age of 70, 17 million individuals lose their lives to chronic illnesses. Moreover, 77 percent of deaths from chronic diseases occur in low- and middle-income nations. And these numbers are expected to rise in the future. Therefore, the rising prevalence of chronic diseases is driving the growth of the controlled release drug delivery market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=9930&type=smp
The controlled release drug delivery market covered in this report is segmented –
1) By Technology: Wurster Technique, Coacervation, Micro Encapsulation, Implants, Transdermal, Targeted Delivery, Other Technologies
2) By Release Mechanism: Polymer Based Systems, Micro Reservoir Partition Controlled Drug Delivery Systems, Feedback Regulated Drug Delivery Systems, Activation-Modulated Drug Delivery Systems, Chemically Activated,
3) By Application: Metered Dose Inhalers, Injectable, Transdermal and Ocular Patches, Other Applications
4) By End User: Hospitals, Clinics, Peronal, Research, Other End Users
Technological advancement is a key trend gaining popularity in the controlled-release drug delivery market. Major companies operating in the controlled-release drug delivery market are adopting new technologies to sustain their position in the market. For instance, in March 2022, Evonik Industries AG, a Germany-based pharmaceutical company, launched UDRATEC SoluFlow. UDRATEC SoluFlow is a novel microparticle technology designed to improve the solubility of active medicinal components in oral medication formulations. This emulsion-based process technique overcomes solubility barriers that traditional production methods cannot. EUDRATEC SoluFlow adds to Evonik Health Care’s range of oral drug delivery system solutions, which includes oral excipients like EUDRAGIT functional polymers, ready-to-fill functional capsules like EUDRACAPTM, and other technologies and services to improve medication performance.
The controlled release drug delivery market report table of contents includes:
1. Executive Summary
2. Controlled Release Drug Delivery Market Characteristics
3. Controlled Release Drug Delivery Market Trends And Strategies
4. Controlled Release Drug Delivery Market – Macro Economic Scenario
5. Global Controlled Release Drug Delivery Market Size and Growth
.
.
.
26. South America Controlled Release Drug Delivery Market
27. Brazil Controlled Release Drug Delivery Market
28. Middle East Controlled Release Drug Delivery Market
29. Africa Controlled Release Drug Delivery Market
30. Controlled Release Drug Delivery Market Competitive Landscape And Company Profiles
Top Major Players:
- Johnson & Johnson Services Inc
- Merck & Co. Inc
- Alkermes PLC
- Coating Place Inc
- Corium International Inc
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
